Ertapenem - wikipedia Ertapenem Ertapenem Clinical data Trade names Invanz AHFS / Drugs.com Monograph License data EU EMA : by INN Pregnancy category AU : B3 US : B ( No risk in non-human studies ) Routes of administration Intramuscular, intravenous ATC code J01DH03 ( WHO ) Legal status Legal status In general : ℞ ( Prescription only ) Pharmacokinetic data Bioavailability 90 % ( intramuscular ) Protein binding Inversely proportional to concentration ; 85 to 95 % Metabolism Minor hydrolysis of beta - lactam ring, CYP not involved Biological half - life 4 hours Excretion Renal ( 80 % ) and fecal ( 10 % ) Identifiers IUPAC name ( 4R, 5S, 6S ) - 3 - ( ( 3S, 5S ) - 5 - ( ( 3 - carboxyphenyl ) carbamoyl ) pyrrolidin - 3 - yl ) sulfanyl - 6 - ( 1 - hydroxyethyl ) - 4 - methyl - 7 - oxo - 1 - azabicyclo ( 3.2. 0 ) hept - 2 - ene - 2 - carboxylic acid CAS Number 153832 - 46 - 3 PubChem CID 150610 DrugBank DB00303 ChemSpider 132758 UNII G32F6EID2H KEGG D04049 ChEBI CHEBI : 404903 ChEMBL CHEMBL1359 Chemical and physical data Formula Molar mass 475.516 g / mol 3D model ( JSmol ) Interactive image SMILES O = C ( O ) c1cc ( ccc1 ) NC ( = O ) ( C@H ) 4NC ( C @ @ H ) ( S C3 = C ( \N2C ( = O ) ( C@H ) ( ( C@H ) ( O ) C ) ( C@H ) 2 ( C@H ) 3C ) C ( = O ) O ) C4 InChI InChI = 1S / C22H25N3O7S / c1 - 9 - 16 - 15 ( 10 ( 2 ) 26 ) 20 ( 28 ) 25 ( 16 ) 17 ( 22 ( 31 ) 32 ) 18 ( 9 ) 33 - 13 - 7 - 14 ( 23 - 8 - 13 ) 19 ( 27 ) 24 - 12 - 5 - 3 - 4 - 11 ( 6 - 12 ) 21 ( 29 ) 30 / h3 - 6, 9 - 10, 13 - 16, 23, 26H, 7 - 8H2, 1 - 2H3, ( H, 24, 27 ) ( H, 29, 30 ) ( H, 31, 32 ) / t9 -, 10 -, 13 +, 14 +, 15 -, 16 - / m1 / s1 Key : JUZNIMUFDBIJCM - ANEDZVCMSA - N ( what is this ? ) ( verify ) Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. It is structurally very similar to meropenem in that it possesses a 1 - β - methyl group. Other members of the carbapenem group ( imipenem, doripenem, and meropenem ) are broadly active antibacterials that are used for infections caused by difficult to treat or multidrug - resistant bacteria ( such as ESBL expressing Klebsiella pneumonia ). They have very short serum half - lives and must be administered by intravenous infusion every 6 to 8 hours. Ertapenem differs from other carbapenems in having a somewhat less broad spectrum of activity ( not against Pseudomonas aeruginosa ), and in that its extended serum half - life allows it to be administered once every 24 hours. Contents 1 Indications 2 Dosage 3 Pharmacokinetics 3.1 Resistance 4 Side - effects 5 References Indications Ertapenem has been designed to be effective against Gram - negative and Gram - positive bacteria. It is not active against MRSA, ampicillin - resistant enterococci, Pseudomonas aeruginosa, or Acinetobacter species. Ertapenem also has clinically useful activity against anaerobic bacteria. Ertapenem has been shown to be active against most isolates of the following micro-organisms in vitro and in clinical infections. Aerobic and facultative gram - positive microorganisms : Staphylococcus aureus ( methicillin - susceptible isolates only ), Streptococcus agalactiae, Streptococcus pneumoniae ( penicillin - susceptible isolates only ), Streptococcus pyogenes, Note : Methicillin - resistant staphylococci and Enterococcus spp. are resistant to ertapenem. Aerobic and facultative gram - negative microorganisms : Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Anaerobic microorganisms : Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Porphyromonas asaccharolytica, Prevotella bivia, Ertapenem is marketed by Merck as a first - line treatment for community - acquired infections. It should not be used as empirical treatment for hospital - acquired infections because of its lack of activity against Pseudomonas aeruginosa. In practice, it is reserved primarily for use against Extended spectrum beta - lactamase ( ESBL ) - producing and high level AmpC - producing Gram - negative bacteria. Dosage Ertapenem is dosed as 1 g given by intravenous injection over 30 minutes, or 1 g diluted with 3.2 ml of 1 % lidocaine given intramuscularly. There is no oral preparation of ertapenem available. Ertapenem can not be mixed with glucose. The marketing slogan for ertapenem is `` The Power of One '', because the dose is one gram, once a day. Pharmacokinetics Unlike imipenem and meropenem, ertapenem is highly protein - bound, which results in a longer half - life ( 4 hours ). Ertapenem is excreted primarily ( 80 % ) by the kidneys. Metabolism by the liver is not clinically important and does not affect dosing. Patients on haemodialysis should be given ertapenem at least 6 hours before dialysis. If it is given less than six hours before dialysis, the patient should be given an additional dose of 150 mg IV after dialysis. Ideally, patients on haemodialysis should be given ertapenem immediately following dialysis. Resistance Acquired resistance to ertapenem is usually mediated by up - regulation of efflux mechanisms and by the selection of porin - deficient mutants. Organisms that produce a metallo - β - lactamase are innately immune to ertapenem ( as well as all carbapenems ). Side - effects There are a few adverse effects of ertapenem like confusion and headache, which may worsen to convulsions and seizures. The only absolute contra - indication is a previous anaphylactic reaction to ertapenem or other β - lactam antibiotic. There are no studies done in pregnant women, so the manufacturers can not comment on its safety in pregnancy. In 2006, Ertapenem became approved for pediatric use in certain infections. Ertapenem is not recommended for children under 3 months of age and children with meningitis. As with many antibiotics, Clostridium difficile colitis has been associated with its use. References Jump up ^ Papp - Wallace KM, Endimiani A, Taracila MA, Bonomo RA ( November 2011 ). `` Carbapenems : past, present, and future ''. Antimicrob. Agents Chemother. 55 ( 11 ) : 4943 -- 60. doi : 10.1128 / AAC. 00296 - 11. PMC 3195018. PMID 21859938. Jump up ^ Product Monograph. Invanz : ertapenem for injection Antibiotics active on the cell wall and envelope ( J01C - J01D ) Intracellular Inhibit peptidoglycan subunit synthesis and transport : NAM synthesis inhibition ( Fosfomycin ) DADAL / AR inhibitors ( Cycloserine ) bactoprenol inhibitors ( Bacitracin ) Glycopeptide Inhibit PG chain elongation : Vancomycin ( Oritavancin Telavancin ) Teicoplanin ( Dalbavancin ) Ramoplanin β - lactams / ( inhibit PBP cross-links ) Penicillins ( Penams ) Narrow spectrum β - lactamase sensitive ( 1st generation ) Benzylpenicillin ( G ) Benzathine benzylpenicillin Procaine benzylpenicillin Phenoxymethylpenicillin ( V ) Propicillin Pheneticillin Azidocillin Clometocillin Penamecillin β - lactamase resistant ( 2nd generation ) Cloxacillin ( Dicloxacillin Flucloxacillin ) Oxacillin Nafcillin Methicillin Extended spectrum Aminopenicillins ( 3rd generation ) Amoxicillin Ampicillin ( Pivampicillin Hetacillin Bacampicillin Metampicillin Talampicillin ) Epicillin Carboxypenicillins ( 4th generation ) Ticarcillin Carbenicillin / Carindacillin Temocillin Ureidopenicillins ( 4th generation ) Piperacillin Azlocillin Mezlocillin Other Mecillinam ( Pivmecillinam ) Sulbenicillin Penems Faropenem Ritipenem Carbapenems Ertapenem Antipseudomonal ( Doripenem Imipenem Meropenem ) Biapenem Panipenem Cephalosporins / Cephamycins ( Cephems ) 1st generation Cefazolin Cefalexin Cefadroxil Cefapirin Cefazedone Cefazaflur Cefradine Cefroxadine Ceftezole Cefaloglycin Cefacetrile Cefalonium Cefaloridine Cefalotin Cefatrizine 2nd generation Cefaclor Cefotetan Cephamycin ( Cefoxitin Cefprozil Cefuroxime Cefuroxime axetil Cefamandole Cefminox Cefonicid Ceforanide Cefotiam Cefbuperazone Cefuzonam Cefmetazole ) Carbacephem ( Loracarbef ) 3rd generation Cefixime Ceftriaxone Antipseudomonal ( Ceftazidime Cefoperazone ) Cefdinir Cefcapene Cefdaloxime Ceftizoxime Cefmenoxime Cefotaxime Cefpiramide Cefpodoxime Ceftibuten Cefditoren Cefetamet Cefodizime Cefpimizole Cefsulodin Cefteram Ceftiolene Oxacephem ( Flomoxef Latamoxef ) 4th generation Cefepime Cefozopran Cefpirome Cefquinome 5th generation Ceftaroline fosamil Ceftolozane Ceftobiprole Veterinary Ceftiofur Cefquinome Cefovecin Monobactams Aztreonam Tigemonam Carumonam Nocardicin A β - lactamase inhibitors Penam ( Sulbactam Tazobactam ) Clavam ( Clavulanic acid ) Avibactam Vaborbactam Combinations Amoxicillin / clavulanic acid Imipenem / cilastatin Ampicillin / flucloxacillin Ampicillin / sulbactam ( Sultamicillin ) Ceftazidime / avibactam Piperacillin / tazobactam Ceftolozane / tazobactam cefoperazone / sulbactam Meropenem / vaborbactam Other polymyxins / detergent Colistin Polymyxin B depolarizing Daptomycin Hydrolyze NAM - NAG lysozyme Tyrothricin Gramicidin Tyrocidine Isoniazid Teixobactin WHO - EM Withdrawn from market Clinical trials : Phase III Never to phase III Merck & Co., Inc. Corporate directors : Richard Clark Johnnetta Cole William Harrison William Kelley Rochelle Lazarus Thomas Shenk Anne Tatlock Samuel Thier Wendell Weeks Peter Wendell Products : Alendronate Aprepitant Ertapenem Ezetimibe Ezetimibe / simvastatin Finasteride Fosaprepitant Indinavir Losartan Lovastatin Montelukast Omarigliptin Raltegravir Rizatriptan Rofecoxib Simvastatin Sitagliptin Vorinostat Publications : The Merck Manuals Index Manual Veterinary Geriatrics Retrieved from `` https://en.wikipedia.org/w/index.php?title=Ertapenem&oldid=806402530 '' Categories : Carbapenem antibiotics Benzoic acids Anilides Pyrrolidines Hidden categories : Template : drugs.com link with non-standard subpage Drugs with non-standard legal status Articles with changed KEGG identifier Drug has EMA link Drugboxes which contain changes to verified fields All articles with unsourced statements Articles with unsourced statements from October 2007 Talk Contents About Wikipedia تۆرکجه Cymraeg Deutsch Español Français Italiano Nederlands Norsk Polski Português Српски / srpski Srpskohrvatski / српскохрватски Svenska Українська 中文 7 more Edit links This page was last edited on 21 October 2017, at 20 : 06. Text is available under the Creative Commons Attribution - ShareAlike License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia ® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. About Wikipedia

Question: how long does invanz stay in your system
Answer: 24 hours